pharma: search

Pharma struggles to adapt as patents expire

pharma news, pharma newsletters, pharmaceutical companies, drug industry, dtc, fda, drug approvals, drug trials, biotech, pharma mergers, pharma acquisitions, pharma conferences, pharma patents, drug news, pharma executive, pharma business, pharma marketing

Philips Further Expands Healthcare Business In Emerging Markets By Acquiring India-Based Meditronics

pharma news, pharma newsletters, pharmaceutical companies, drug industry, dtc, fda, drug approvals, drug trials, biotech, pharma mergers, pharma acquisitions, pharma conferences, pharma patents, drug news, pharma executive, pharma business, pharma marketing

AVI BioPharma Strengthens Patent Position in Exon Skipping

pharma news, pharma newsletters, pharmaceutical companies, drug industry, dtc, fda, drug approvals, drug trials, biotech, pharma mergers, pharma acquisitions, pharma conferences, pharma patents, drug news, pharma executive, pharma business, pharma marketing

Watson Pharma unit files lawsuit against Barr Pharma, Barr Labs for OXYTROL patent infringement - Quick Facts

Watson Pharma says data from investigational Oxybutynin Topical Gel study for treatment of Overactive Bladder positive - Update

Barr Pharma. confirms challenge of patent listed by Anesta in connection with Amrix extended-release capsules - Quick Facts

Barr Pharma inks deal to resolve ongoing patent challenges for Nasacort, Allegra D-12, Allegra - Update

Barr Pharma inks deal to resolve ongoing patent challenges for Nasacort, Allegra D-12, Allegra - Update

Barr Pharma unit signs separate settlement deals related to ongoing patent challenges for Nasacort, Allegra D-12, Allegra tablets - Quick Facts

Barr Pharma unit signs separate settlement deals related to ongoing patent challenges for Nasacort, Allegra D-12, Allegra tablets - Quick Facts

Barr Pharma inks deal to resolve ongoing patent challenges for Nasacort, Allegra D-12, Allegra - Update

Orion sues Sun Pharma Global, Inc. in the U.S. to enforce Orion's U.S. Patent No. 5,446,194 covering its proprietary drug Comtan

Orion Corporation filed a patent infringement lawsuit in the United States to enforce its U.S. Patent No. 5,446,194 ("the '194 patent") against Sun Pharma Global, Inc., who seeks to market a generic version of Orion Corporation's proprietary drug, Comtan® in the United States. Comtan contains entacapone and is a product originated by Orion Corporation and marketed in the United States for the treatment of Parkinson's disease by its exclusive licensee, Novartis.

Orion Sues Sun Pharma Global, Inc. in the U.S. to Enforce Orion's U.S. Patent No. 5,446,194 Covering its Proprietary Drug Comtan

ESPOO, Finland, Nov. 12, 2008--Orion Corporation filed a patent infringement lawsuit in the United States to enforce its U.S. Patent No. 5,446,194 ("the '194 patent") against Sun Pharma Global, Inc., who seeks to market a generic version of Orion Corporation's proprietary drug, Comtan® in the United States. Comtan contains entacapone and is a product originated by Orion Corporation and marketed in the United States for the treatment of Parkinson's disease by its exclusive licensee, Novartis.

My Life as a Compliance Analyst: The Case for Pharma Reps

My Life as a Compliance Analyst: The Case for Pharma Reps - DiabetesMine: diabetes, life, health, community on Dining on Strength

Tempo Pharmaceuticals, Inc. Announces Name Change to Cerulean Pharma Inc.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 24, 2008 - Tempo Pharmaceuticals, Inc., a biopharmaceutical company focused on novel, intelligently designed, nanoparticle-based drugs, today announced that the Company has changed its name to Cerulean Pharma Inc., effective immediately. Cerulean is a word which is derived from the Latin term meaning "heaven or sky" and better expresses the company's aspirations to have a significant impact on disease. The Company's new website is www.ceruleanrx.com.

Watson sues Barr for Oxytrol patent infringement - update

Watson Pharma unit files lawsuit against Barr Pharma, Barr Labs for OXYTROL patent infringement - Quick Facts

Pharma struggles to adapt as patents expire

NEW YORK (Reuters) - New threats to drug makers' revenues are rising even as the industry maneuvers to plug huge holes from looming patent expirations.

Pharma struggles to adapt as patents expire

NEW YORK (Reuters) - New threats to drug makers' revenues are rising even as the industry maneuvers to plug huge holes from looming patent expirations.

Pharma industry attacked over patent strategies

This article is part of MIP Week, a weekly email newsletter written by the editors of Managing IP magazine. Take a one week trial to Managing IP and find many more related articles.

Peregrine Pharma gets US patent for anti-viral applications of phospholipid-targeting antibodies

Peregrine Pharmaceuticals, Inc, a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of serious viral infections and cancer, announced that the US Patent and Trademark Office has issued US Patent Number No 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids.

Barr Pharma unit launches Amrix patent challenge

said Wednesday that its Barr Laboratories subsidiary has initiated a challenge of the patent listed by Anesta Corp. in connection with its Amrix extended-release capsules. Barr said that it has filed with U.S. Food and Drug Admistration an Abbreviated New Drug Application to manufacture a generic version of Amrix, a muscle relaxant. Cephalon Inc.

RXi Pharma names Konstantinos Andrikopoulos VP, Legal Counsel and Chief Intellectual Property Counsel - Quick Facts

(RTTNews) - RXi Pharmaceuticals Corp. (RXII: News ) announced that it appointed Konstantinos Andrikopoulos as Vice President, Legal Counsel and Chief Intellectual Property Counsel.

Inotek Pharma gets US patent for glaucoma and contrast-induced nephropathy

Inotek Pharmaceuticals Corporation announced that the United States Patent and Trademark Office has issued two new patents covering the company's two lead clinical compounds. US Patent number 7,423,144 relates to INO-8875, in clinical development as a novel treatment for glaucoma and US Patent number 7,432,369 relates to INO-4885, in clinical development for the prevention of contrast-induced nephropathy.

Adeona Pharma gets US patent for oral Tiomolibdate Diammonium for Alzheimer's disease

Adeona Pharmaceuticals, Inc, a late-stage pharmaceutical company developing innovative drug candidates for the treatment of autoimmune and central nervous system diseases, announced the issuance of US Patent No 7,416,741 containing claims covering the use of thiomolybdates such as oral tiomolibdate diammonium (USAN name for oral tetrathiomolybdate, or TTM) for the treatment of Alzheimer's disease (AD).

Adeona Pharma. Granted US patent for use of oral tiomolibdate diammonium to treat Alzheimer's disease - Quick Facts

Austral Pacific Energy farms down 80% interest in PEP 38524 to Australian Worldwide Exploration - quick facts

Indian pharma cos fail to compete with foreign players in securing product patents for innovations

Indian pharmaceutical companies and individuals together could grab just above 15 per cent of the total product patents granted to pharmaceutical inventions and innovations in the past three years from January 1, 2005, ever since the country moved into the product patent regime from process patents.

Memory Pharma reveals issuance of US Patent for series of nicotinic alpha-7 receptor agonists - Quick Facts

(RTTNews) - Memory Pharmaceuticals Corp. (MEMY: News ) announced the issuance of U.S. Patent, which provides composition of matter patent protection for a series of nicotinic alpha-7 receptor agonists. These include R3487/MEM 3454 and R4996/MEM 63908, which are both being developed in partnership with Roche for the treatment of cognitive disorders such as Alzheimer's disease and cognitive impairment associated with schizophrenia.

UPDATE: EU: Pharma Cos Abuse Patents To Block Competition

(Dow Jones)- Big pharmaceutical companies abuse their position in the marketplace to delay and block new, often cheaper, drugs from coming to market, the E.U. Commission said Friday.

2nd UPDATE EU Pharma Cos Abuse Patents To Block Competition (DJ)

By Peppi Kiviniemi Of DOW JONES NEWSWIRES BRUSSELS -(Dow Jones)- Big pharmaceutical companies abuse their position in the marketplace to delay and block cheaper versions of their drugs from coming to market, the E.U. Commission said Friday.

Search took 0.02 seconds.